FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot

FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot


Justin Sullivan | Getty Images

The Food and Drug Administration has laid out a road map for what Covid-19 vaccination may look like moving forward.

In a briefing document published Monday, the FDA said the vaccines will probably need an annual update as the virus continues to evolve. The agency would select the Covid strain for the vaccine in the spring so the updated shots could roll out every September in time for a fall vaccination campaign.

Most people would receive one shot to restore their protection against the virus moving forward, according to the briefing document. This would apply to people who have been exposed to the virus’s spike protein at least twice, either through vaccination or infection.

But older adults and people with compromised immune systems may need two doses, according to the proposed vaccination schedule. Young children who have received only one shot previously would also get two doses.

The FDA released the road map ahead of a meeting of the agency’s independent vaccine experts scheduled for Thursday. The expert panel will vote on whether to make all Covid vaccines in the U.S. bivalent shots, meaning they protect against both the omicron BA.5 subvariant as well as the original strain of Covid discovered in Wuhan, China, in late 2019.

Currently, only Moderna’s and Pfizer’s booster doses target the omicron variant. If adopted, the primary series would also contain the omicron strain.

The proposed system for updating Covid vaccines resembles how the FDA selects flu shots every year. The agency said it could update and rollout the Covid vaccines without clinical data, which is also the case with the annual process to change the flu shot.

The Centers for Disease Control and Prevention on Thursday is also expected to provide more information about an investigation into what it has described as a “very unlikely” risk of stroke in seniors who received Pfizer’s omicron booster.

The CDC received preliminary safety concern data from its Vaccine Safety Datalink late last year. A subsequent review for four other major databases did not identify an increased risk for stroke, but the CDC investigation is ongoing.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill
Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Read More
Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat
Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Read More
Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More